Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone.

Abstract

BACKGROUND:

Macular edema (ME) treatment has benefited from the recent intravitreal pharmacotherapy development of an intravitreal implant of dexamethasone (Ozurdex(®), Allergan, Irvine, Calif., USA). However, its efficiency has never been illustrated beyond 3 injections.

CASE PRESENTATION:

We report the case of a 75-year-old woman with inferior branch vein occlusion, who, after laser photocoagulation treatment and recurrence after intravitreal injection of triamcinolone, benefited from 4 injections of Ozurdex. Her macular thickness and visual acuity (VA) progression were assessed for 17 months.

CONCLUSIONS:

This case report highlights the quick efficiency of Ozurdex on VA and ME with good reproducibility and tolerance, and without tachyphylaxis phenomenon. This is the first illustrated description of 4 consecutive injections for ME induced secondary to retinal vein occlusion.

• Authors: Frederic Matonti, Louis Hoffart, Christophe Baeteman, Danièle Denis
• Journal: Case reports in ophthalmology (Case Rep Ophthalmol) Vol. 3 Issue 3 Pg. 339-42 (Sep 2012) ISSN: 1663-2699 [Electronic] Switzerland
• PMID: 23139679 (Publication Type: Case Reports)